Tunkel A R, Scheld W M
Department of Internal Medicine (Infectious Diseases), Medical College of Pennsylvania, Philadelphia 19129.
Clin Microbiol Rev. 1993 Apr;6(2):118-36. doi: 10.1128/CMR.6.2.118.
Bacterial meningitis remains a disease with associated unacceptable morbidity and mortality rates despite the availability of effective bactericidal antimicrobial therapy. Through the use of experimental animal models of infection, a great deal of information has been gleaned concerning the pathogenic and pathophysiologic mechanisms operable in bacterial meningitis. Most cases of bacterial meningitis begin with host acquisition of a new organism by nasopharyngeal colonization followed by systemic invasion and development of a high-grade bacteremia. Bacterial encapsulation contributes to this bacteremia by inhibiting neutrophil phagocytosis and resisting classic complement-mediated bactericidal activity. Central nervous system invasion then occurs, although the exact site of bacterial traversal into the central nervous system is unknown. By production and/or release of virulence factors into and stimulation of formation of inflammatory cytokines within the central nervous system, meningeal pathogens increase permeability of the blood-brain barrier, thus allowing protein and neutrophils to move into the subarachnoid space. There is then an intense subarachnoid space inflammatory response, which leads to many of the pathophysiologic consequences of bacterial meningitis, including cerebral edema and increased intracranial pressure. Attenuation of this inflammatory response with adjunctive dexamethasone therapy is associated with reduced concentrations of tumor necrosis factor in the cerebrospinal fluid, with diminished cerebrospinal fluid leukocytosis, and perhaps with improvement of morbidity, as demonstrated in recent clinical trials. Further information on the pathogenesis and pathophysiology of bacterial meningitis should lead to the development of more innovative treatment and/or preventive strategies for this disorder.
尽管有有效的杀菌抗菌疗法,但细菌性脑膜炎仍然是一种发病率和死亡率令人难以接受的疾病。通过使用感染的实验动物模型,已经收集了大量关于细菌性脑膜炎中可操作的致病和病理生理机制的信息。大多数细菌性脑膜炎病例始于宿主通过鼻咽部定植获得新的病原体,随后发生全身侵袭和严重菌血症。细菌的荚膜通过抑制中性粒细胞吞噬作用和抵抗经典补体介导的杀菌活性,促进了这种菌血症。然后发生中枢神经系统侵袭,尽管细菌进入中枢神经系统的确切部位尚不清楚。通过在中枢神经系统中产生和/或释放毒力因子以及刺激炎症细胞因子的形成,脑膜病原体增加了血脑屏障的通透性,从而使蛋白质和中性粒细胞能够进入蛛网膜下腔。随后会出现强烈的蛛网膜下腔炎症反应,这会导致细菌性脑膜炎的许多病理生理后果,包括脑水肿和颅内压升高。如最近的临床试验所示,辅助地塞米松治疗减轻这种炎症反应与脑脊液中肿瘤坏死因子浓度降低、脑脊液白细胞增多减少以及可能的发病率改善有关。关于细菌性脑膜炎发病机制和病理生理学的更多信息应该会导致开发出更具创新性的针对这种疾病的治疗和/或预防策略。